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abStract
Gelatine is used as an excipient for various pharmaceutical dosage forms, such as capsule shells (both hard and soft), 
tablets, suspensions, emulsions and injections (e.g. plasma expanders). It is also broadly used in various industries 
such as food and cosmetics. Gelatine is a biopolymer obtained from discarded or unused materials of bovine, porcine, 
ovine, poultry and marine industrial farms. The discarded materials can be the skin, tendons, cartilages, bones and 
connective tissues. Gelatine sourced from animals is relatively easy and inexpensive to produce. The potential needs of 
gelatine cannot be overemphasised. Rising demands, health concerns and religious issues have heightened the need for 
alternative sources of gelatine. This review presents the various industrial uses of gelatine and the latest developments 
in producing gelatine from various sources.
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abStrak
Gelatin diguna sebagai eksipien (bahan tambahan) dalam pelbagai bentuk dos farmaseutik seperti kelongsong kapsul 
(keras dan lembut), tablet, ampaian (suspensi), emulsi dan suntikan (contoh: pengembang plasma). Ia juga diguna 
dalam pelbagai industri lain seperti industri makanan dan kosmetik. Gelatin adalah biopolimer yang diperoleh daripada 
bahan-bahan terbuang atau yang tidak diguna daripada haiwan ternakan termasuk lembu, porsin, ovin, unggas dan 
ikan. Bahan-bahan terbuang ini adalah seperti kulit, tendon, rawan, tulang dan tisu penghubung. Gelatin daripada 
sumber haiwan adalah agak mudah dan murah untuk dihasilkan. Potensi gelatin tidak dapat dinafikan. Permintaan yang 
semakin meningkat, masalah kesihatan dan isu-isu agama telah meningkatkan keperluan untuk sumber alternatif gelatin. 
Tinjauan ini membentangkan pelbagai kegunaan gelatin dalam industri dan perkembangan terkini dalam penghasilan 
gelatin daripada pelbagai sumber.
Kata kunci: Farmaseutik; gelatin; kosmetik; makanan; penambah plasma; sumber alternatif
introduction
Discovery and development of new active pharmaceutical 
ingredients (APIs) and excipients have led to the continued 
interest in drug delivery research. Novel excipients are 
now being sought and used by pharmaceutical companies 
to develop new pharmaceutical formulations which can 
efficiently administer drugs into patients. Pharmaceutical 
formulation is defined as a composition or combination 
of an API along with excipients to finally produce a 
pharmaceutical dosage form. This dosage form is known 
as drug or medicine. An API is a component that provides or 
causes the necessary pharmacological effect of a particular 
drug. Various chemicals or biological entities can stand as 
APIs in drugs or medicines. Excipients, on the other hand, 
are usually inactive components of a formulation and are 
also known as additives. Excipients serve specific purposes 
such as binders, disintegrants, diluents, lubricants and 
colourants. They are even used as drug release modifiers to 
promote or aid the process of drug delivery (Bhattacharyya 
et al. 2006; Dangi et al. 2011; Organization 2015). 
Agro-sourced polymer materials such as animal-
sourced polysaccharides and proteins are now used 
extensively as excipients for pharmaceutical formulations 
and are produced in a carefully controlled environment. 
Polymers are macromolecules made up of covalently 
bonded monomers which may be linear, branched, or 
cross-linked with other chains. These are based on natural 
or synthetic polymers (Ige et al. 2012; Rastogi & Samyn 
2015; Yadav et al. 2015). The common natural polymers 
are polysaccharides (chitosan, starch & alginates) and 
proteins (gelatine & silk) 
Besides the pharmaceutical industry, these excipients 
are also utilised in various other industries which include 
food, nutraceuticals, cosmetics, beverages and agriculture. 
They are also employed in chemical engineering, forensic 
science and recreational applications. Figure 1 shows the 
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types of natural agro-sourced polymer materials which are 
commonly used as excipients. 
Table 1 lists the materials which are effectively 
resourced to sustain the growing global need for safe 
and consumable excipients. These materials are given 
the specifi c term ‘generally regarded as safe’ or GRAS. 
Although excipients are costly additions, they are central 
to enhancing the fi nal presentation of any pharmaceutical 
products. Thus, the drive for cheaper sources of these 
materials is important to positively infl uence the market 
price or economic development of the fi nished products. 
Basically, an increase in price of currently available 
excipients is due largely to acute shortage or undersupply of 
the appropriate raw materials. The overall pharmaceutical 
excipient demand is expected to grow at a stable rate of 
about 6.1% from 2016 to 2021, which is about USD8.1 
billion in 2021 and estimated world excipient market 
volume to reach 728.4 kilo tons by 2020 (Markets 
2016; Reports 2016; Research 2016a). There is even 
a confi rmation of the global pharmaceutical excipient 
growth, indicating to reach USD9.3 billion by the end of 
2020, growing at a CAGR of around 7.2% from 2014 to 
2020 (Intelligence 2016). Whereas it was reported in a 
study, drug delivery technology is targeted to increase 
the effi ciency of drug and proposing improved patient 
compliance of any types of drug formulations. Its market 
is anticipated to rise to USD1,504.7 billion by 2020 from 
USD 1,048.1 billion in 2015, with a steady growth rate 
at a CAGR of 7.5% from 2015 to 2020 (Markets 2015). 
Excipients used in injections or parenteral preparations 
alone are expected to rise at a strong pace through 2018. 
Examples of agro-sourced excipients used in parenteral 
formulations are lactose and gelatine (Dangi et al. 2011; 
Thassu et al. 2007; Walker 2015). 
Gelatine is basically sourced from animal protein 
and utilised for various applications since 16th century 
during the late Ming and early qing Dynasties in 
China. Commercial manufacturing of gelatine was 
introduced since the mid-17th century in Holland. By 
the late 18th century, which is during the Napoleonic 
era, claims were made about the food value of gelatine 
and this led to its manufacture in France. It is non-toxic, 
water soluble, biocompatible, inert excipient and an 
economical polypeptide source. Its functions as a valuable 
biologically active and irreplaceable auxiliary ingredient 
especially in parenteral products for the pharmaceutical 
and cosmeceutical industry are due to its viscosity, high 
mechanical strength at different concentrations. It is also 
believed to increase the number of red blood cells and 
haemoglobin thus, the promoting hematopoietic function 
(liu et al. 2014; Nongxuan 2016). Gelatine is a mixture 
of heterogeneous high molecular weight protein derived 
from fi brous collagenous material such as bones, cartilages, 
connective tissues, skin, and tendons of animals (Ha et al. 
2013)(Ha, 2013 #242). Gelatine production worldwide is 
worth about US$1.8 billion in 2013 and is estimated to rise 
even further by 2020 to about US$3.0 billion, with a growth 
rate at about 7.5% CAGR from 2014 to 2020 (Research 
2014). Therefore, to sustain the usage, there is an urgent 
need for new alternative sources of gelatine, which are 
economical, abundantly and sustainably available for the 
potential growing demands in the various aforementioned 
industries.
Further extensive research is being carried out to date 
for the various manufacturing, refi ning gelatine production 
techniques and its applications from alternative sources 
(Gómez-Guillén et al. 2011; Ivanova et al. 2014; Mariod & 
Adam 2013; Mariod & Fadul 2015; Wray & Kaplan 2014). 
The results of these researchers could hopefully shed light 
on uses of alternatively sourced gelatine for its excipient 
or API usage (Gorgieva & Kokol 2011; li et al. 2009; 
Malafaya et al. 2007; Nur Hanani et al. 2014; Paguirigan 
& Beebe 2006; Rose et al. 2014; Rottensteiner et al. 2014; 
Su & Wang 2015; Zhao et al. 2016).
Gelatine sourced from poultry by-products, for 
example, is an interesting option and is now extensively 
studied. Malaysia being a self-suffi cient poultry meat 
production country shows an expanding output, which is 
FIGURE 1. Classifi cation of natural agro-sourced polymers
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TABlE 1. Materials resourced from animal source as natural excipients and its applications
Types of natural 
excipients Animal source
Type of material from 
natural source Uses/applications
Beeswax Honey bees Honeycomb emulsifiers, thickeners or stiffening or hardening 
agents and polishing agent, treatment for allergy, 
haemorrhoids, stimulate hair growth, antiseptic and 
anti-inflammatory properties, emollient properties 
and preventing and treating stretch marks, anti-ulcer 
agent, wax agent
Chitosan Shrimp, crab, lobster and 
other shellfish
Exoskeleton or shell Binding agent, coating/ film forming agent, 
controlled release/slow/sustain release agent, 
bioadhesive polymer agent, absorption/permeability 
enhancing properties thus used in ocular, nasal, 
buccal, gastrointestinal, peroral, vaginal, and 
transdermal drug delivery vehicles, diluent, 
disintegrant, mucoadhesive, tablet binder, viscosity 
increasing agent
Cochineal Insect Dactylopius coccus 
family Dactylopiidae 
living on cacti
extracted from body and 
eggs and mixed with 
aluminium or calcium 
salts to form carmine dye
Colouring agent or colourants
Cantheride/ 
Cantharidin
Insect Hycleus lugens 
or blister beetle/ lytta 
vesicatoria or Spanish fly
Body fluid of insect Blistering agent
Honey Honey bees Honeycomb Sweetening agent, antioxidant, anti-inflammatory, 
moisturizer, demulcent, antiseptic
lactose Cattle, Sheep, Goats Milk Binding agent, diluent, filler agent, dry powder 
inhaler carrier, disintegrant, 
lanolin/wool fat Sheep wax secreted by 
subaceous glands 
Emulsifier or emulsifing agent, ointment base.
lecithin Chicken egg, soyabeen, 
peanut, sunflower, 
rapseed.
Egg yolk, corn or ground 
oil
Emollient, emulsifying agent, solubilizing agent, 
suppository base
lard Porcine visceral fat deposit 
surrounding the kidneys 
and inside the loin
Ointment bases
Musk Musk deer, Moschus 
moschiferus linn. 
Family: Cervidae
dried secretion from 
preputial follicle
Perfumery agent
Spermaciti/ 
spermaceti
Whale of Physeter 
microcephalus linn.
Head of sperms of whale Emollient, stiffening agent, ointment/emulsion base
Suet/ tallow/
stearic acid
Sheep, cattle Hard white fat around 
kidneys and loins
granulating agent, emulsifying agent, solubilizing 
agent, lubricant, softening agent
Shellac tiny lac insect laccifer 
lacca Kerr. (Kerria lacca) 
Family lacciferidae 
(Coccidae)
resinous protective 
secretion
Coating agent in tablets, micro-encapsulation, 
control release preparation, In cosmetics binding 
agent for lipstick, lacquers, nail polishes, eye 
shadows. In food for preparations of chocolates, 
lozenges, coffee beans
Gelatine Bovine, Porcine, 
Ovine (sheep), 
Caprine (goat) and fish
Bones, skin, hide Stabilizer, coating/film-forming agent, gelling 
agent, suspending agent, binding agent, viscosity-
increasing agent, clarifying agent, suppository bases, 
vaginal drug delivery, regenerative joint cartilage, 
maintenance of skin health
in line with expectations for domestic demand growth. The 
chicken meat consumption rate is about 40 kg per year, 
per capita consumption. Hence, with the average growth 
of 1.5-2% in per capita consumption, it is projected that 
the poultry meat production will rise to 5-13.4% by 2017-
2018 (Abdullah et al. 2016; Chowdhury et al. 2014; Poultry 
2014; Site 2015). The tremendous growth in poultry 
production is due to the shifting of consumer preference 
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resulting in an increase in demand of poultry livestock and 
by-products (Rustad et al. 2011). 
This review presents new alternative sources of agro-
based gelatine that may be useful in fulfilling the current 
needs for downstream agro-based products. 
Gelatinein Generic or bioSiMilar PharMaceutical 
ForMulationS
Pharmaceutical formulations are divided into originator or 
innovator products. Innovator drugs are newly-developed 
pharmaceutical formulations which are usually patented 
by the founding pharmaceutical companies or originators. 
Generic and/or biosimilar pharmaceutical formulations, on 
the other hand, are pharmaceutical products produced by 
non-originator companies from formulations with expired 
patents. Both generic and biosimilar should not differ from 
the referenced or original product ‘approved before’ and 
‘on market’ and is expected to have substantially similar 
clinical results (in terms of safety profile and efficacy) 
(Wang 2011). 
The use of entrepreneurial biotechnology and 
genetic engineering has made biological products to 
be sophisticatedly developed drugs. Biotechnological 
advancement has managed to introduce these products 
such as insulin, human growth protein somatostatin, 
hepatitis B vaccine and others to be introduced for human 
medical treatment. Manufacturing of these products into 
generic drugs is now rather difficult as the processes 
involved are highly specialised. Making a generic 
version of it is thought to be impossible, so much so that 
patenting the biotechnologically developed drug would 
be considered sufficient for research advancement. But 
now, as the patents have expired and with the progress of 
pharmaceutical development, copies of these biological 
products were found to be available. Thus, bringing forth 
a new type of class called biosimilar drugs. A biosimilar 
has an additional characteristic in which it is a biological 
product and is produced in or from a living system and 
is manufactured through processes that are reproducible, 
consistent, having the same safety, potency, and purity as 
the originator product. 
The difference between formulations of a particular 
biosimilar product may be due to the presence of differing 
excipients added. Biosimilar products formulations 
should be ‘highly or nearly similar’ even though there 
are minor differences in the use of excipients or similar 
excipients from a different source (Niazi 2016; Roger 
2006). The difficulty for developers of any biosimilar 
is that there is usually no direct access to originator 
companies’ proprietary data. Therefore, the developer 
of a biosimilar, has to purchase the reference medicine 
from a pharmacy and then purify the drug substance, and 
engineer a process to produce the biosimilar that is, the 
development of a biosimilar requires the establishment of 
a new manufacturing process ‘from scratch’.
Due to the complex production method of biological 
medicines, the active substance may differ slightly between 
the biological reference and the biosimilar medicine. 
‘Slight’ differences can have a major impact (Prugnaud 
& Trouvin 2012; Sekhon & Saluja 2011). For example, in 
demonstrating the biosimilarity of two plasma expanders 
in which a new biosimilar is formulated using bovine 
gelatine while the referenced product uses a different 
gelatine source as well as different methods of processing 
as compared to conventional processes. The results 
showed slight differences in characteristics may be found 
in these products. The new product can still be regarded 
as a biosimilar to the referenced product as long as the 
differences are within acceptable range as designated in 
standard pharmacopoeias (Saw et al. 2012). A new drug 
or medicine and having/demonstrating similar or within 
acceptable range of pharmaceutical characteristics to 
the originator products are further compared through 
bioequivalent studies (Dunne et al. 2013).
The World Health Organization has defined a 
generic drug as a pharmaceutical product, usually 
intended to be interchangeable with an originator 
or innovator product that is manufactured without a 
licence from the originator or innovator company and 
marketed after the expiry date of the patent or other 
exclusive rights. Whereas US FDA has further defined 
generic drug as a drug product or pharmaceutical 
drug that is comparable or equivalent to a brand name 
product/reference listed drug product dosage form, 
strength, route of administration, quality, performance 
characteristics and intended use. Thus, it can be said that 
classifying any generic drug will depend on its ‘active 
pharmaceutical ingredient or API’ (as mentioned earlier) 
and is the main functional chemical that has or gives the 
desired biological effect. 
A biopharmaceutical is also known as a biological 
medicinal products defined as any pharmaceutical drug 
product manufactured using biotechnology, in or extracted 
from or semi-synthesised from biological sources and 
different from chemically synthesized pharmaceuticals 
which includes vaccines, blood, blood components, 
allergenics, somatic cells, gene therapies, tissues, 
recombinant therapeutic protein and living cells used in 
cell therapy and composed of sugar, proteins or nucleic 
acid or complex combinations of these substances or may 
be living cells or tissues. It can further be explained as 
biological products or biopharmaceuticals, is a class of 
drugs based on proteins having a therapeutic effect. They 
are isolated from natural sources such as human, animal or 
microorganisms and are differentiated due to the presence 
of large molecule size API (MW ≥ 20,000 Daltons). 
A biosimilar was known as a generic version 
of biological drugs or products, has an additional 
characteristic in which it is a biological product, and is 
produced in or from a living system, and is manufactured 
through processes that are reproducible and consistent. 
Whereas literature suggests that biosimilar is comparable 
but not identical to the reference product and neither a 
generic version of an originator product and does not 
ensure therapeutic equivalence. The difference between 
formulations of a particular biosimilar product may be due 
to the presence of differing added excipients. Biosimilar 
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products formulations should be ‘highly or nearly similar’ 
even though there are minor differences in the use of 
excipients or similar excipients from a different source. 
These new products can be regarded as a pharmaceutical 
biotechnology product or biopharmaceutical proteins or 
amino acid sequence as the differences are within the 
acceptable range as designated in standard pharmacopoeias 
(Saw et al. 2012).
CHEMISTRY OF GElATINE
Gelatine is a naturally occurring, biocompatible protein 
polymer. It is a stable, heterogeneous mixture of amino 
acids having a structure, which is very favourable 
for different chemical modification such as for drug 
attachment. Gelatine is obtained by thermal denaturation 
of the protein collagen, which is the structural mainstay 
and the most common protein in the animal kingdom. 
Gelatine involves the mixture of heterogeneous high 
molecular weight proteins, which have gone through a 
separation or partial separation, or destruction of the rods 
and chains of the tertiary, secondary and primary structure 
of native collagens. Hydrogen bonds are destroyed by 
acid or alkaline treatment of skin, tendons, cartilages, 
bones and connective tissues from animal sources 
resulting in the loss of the triple-helix conformation 
(Figure 2) (Gorgieva & Kokol 2011; Mariod & Adam 
2013). During the conversion of collagen to gelatine, 
random rearrangements of the chains give rise to mixtures 
of different molecular weight compounds – α-chains 
(one polymer chain), β-chains (two α-chains covalently 
cross-linked) and γ-chains (three covalently cross-linked 
α-chains) (Figure 2) (Totre et al. 2011). Gelatine consists 
of 85-92% protein, 2-4% mineral salts and 8-12% water. 
In solution form, gelatine has a unique protein behaviour 
in which it can be fabricated for its different industrial 
use by modifying its isoelectric points. The processes 
applied to obtain the gelatine are differentiated by Type 
A (acidic treatment) and Type B (alkaline treatment). The 
availability of these two distinct processes has facilitated 
to the robustness in the production of gelatine (Gorgieva 
& Kokol 2011; Totre et al. 2011)
DEMAND FOR GElATINE ExCIPIENTS
Production of gelatine in 2011 was nearly 373,300 
tonnes in which porcine skin was the major source (42%) 
followed by bovine hide (29%) and bovine/porcine bones 
(27%) (Figure 3)(Research 2015). Gelatine production 
is expected to continue to grow at a steady rate of 3.8% 
from 2014 to 2020 and further by 5.3% from 2016 to 
2024. The market for gelatine by 2020 would thus be 
worth at USD3.18 billion and is further expected to reach 
USD4.08 billion by 2024 as forecasted in the new report 
by Grand View Research, Inc. report, ‘Global Gelatin 
Market Analysis and Segment Forecast to 2020’ and 
‘Gelatin Market Size Expected To Reach $4.08 Billion 
By 2024’ (Research 2016b). Gelatine use in relation 
to the gelatine market share for 2013 was highest in 
the food and beverages sector (28%), followed by 
nutraceuticals (25.8%) and pharmaceuticals (21%). Its 
use in the cosmetic industry was 5.5% (Figure 4). The 
use of gelatine in these industries is expected to increase 
further by 2020 to about 480,000 metric tonnes, driven 
FIGURE 2. The conversion of triple helix of collagen to gelatine and its basic structure (Gorgieva & Kokol 2011)
Triple Helic 
Collagen
Gelantine B/Acidic Gelatine Gelantine A/Basic Gelatine 
pH < 4.7-5.4  Δ WaterpH < 6-9  Δ Water
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by increasing use of food, drugs and supplements in the 
pharmaceutical industry (Analysts 2016). Along with 
the advancements in drug delivery technology caused 
the evolvement of new excipients as novel dosage forms 
to fulfi l specifi c functions which directly or indirectly 
infl uence the extent and or rate of drug release. This in 
return enrages the development of new and modifi ed 
excipient source continue to emerge for better drug 
delivery performance (Mohamad et al. 2015).
Due to a tremendous increase in demand, there is 
an expectation of a drop in the supply of raw materials 
derived from the hides of bovine or porcine, which makes 
up to 90% of the gelatine source. This shortage of supply 
was notably cited due to the cost of complying with the 
new EU Sow Housing Regulations, infl ated the cost of 
production and higher feed prices (Morrison 2012). Other 
factors that can negatively infl uence the supply of gelatine 
are recent weather conditions (lengthy dry spell) as well 
as stagnated bovine slaughtering and production growth 
in major gelatine producing countries such as India.
Moreover, prices in China have risen due to stricter 
production standards and regular inspections imposed after 
a number of capsules for pharmaceuticals were found to 
have been produced from scraps of leather containing 
excessive levels of chromium. Therefore, an exigent 
exploration into other sources of gelatine is needed. This 
may include studies into gelatine production from avian 
or even fi sh (Abdullah et al. 2016). 
The development of alternative gelatine sources 
provides market opportunities for the industry. Demands 
in halal gelatine have created a strong infl uence in this 
sector. It is expected that the halal food and pharmaceutical 
industries would grow at about 12% of the total global trade 
in agro-food and pharmaceutical products (Alqudsi 2014; 
Sahilah et al. 2012; Shah & Yusof 2014). This growing 
market is basically due to the projected Muslims population 
of about 30% of the world’s population by 2025 (Karim 
& Bhat 2008). 
diFFerent tyPeS oF Gelatine raW MaterialS
Gelatine is basically sourced from different biopolymer 
raw materials such as indicated below: 
FIGURE 3. Global gelatine demand according to source/raw material in 2011 (Transparency Market Research 2015: Global 
Gelatin Market to Expand at 6.75% CAGR because of Greater Application Scope in Various End-use Industries http://www.
transparencymarketresearch.com/pressrelease/gelatin.htm)
Global demand for gelatine by source 2011
Porcine skin gelatine
Bovine hide
Bovine/porcine bone
Other source
Polyniers
Alcohols
Sugar & Others
Minerals
FIGURE 4. Global gelatine application in various industrial applications - 2013 (Grand View Research, Inc. 2014)
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BOVINE
For decades, bovine edible products and by-products, 
which include organs, fat, skin, feet, bone, blood, 
abdominal and intestinal contents are mainly produced 
by slaughterhouses. The literature indicates about 66% 
of live weights, which are by-products such as skin, bone 
and feet are utilised as starting material for other industrial 
products such as gelatine.
Shortage of bovine-based raw materials for 
pharmaceuticals (which include gelatine) has been a great 
highlighted in countries such as India, due to religious 
concerns (Morrison 2012b, 2012c). India has a majority 
Hindu population (80%) where the religion reserves cows 
as holy, thus an increase in cow slaughter seems unlikely. 
Due to this since early 2000, there has been research 
undertaken throughout the world to find new developing 
sources due to shortage also in agricultural land, diseases 
and shift in human consumption for health reasons.
PORCINE
Porcine-based raw materials are one of the biggest sources 
of gelatine within the gelatine industry. However, due to 
the European Union’s changes to pig farming laws in early 
2013, the price of gelatine-based products is expected to 
increase by 5% because of shortages of porcine skin as 
well as bovine bones. This is because the farmers would 
have to spend more on housing the livestock (Morrison 
2012a). 
Besides religious concerns of the Hindu religion on 
bovine-based gelatine, Jew and Muslims are also very 
much uncomfortable about porcine-based gelatine. Jews, 
Muslims and Hindus represent ¾ of the world population, 
making the search for alternative gelatine source, which 
is acceptable to these religious populations, a pragmatic 
quest. The Halal market alone made about $700 billion in 
2013 (Barry 2014). 
OVINE AND CAPRINE
Ovine (sheep and goat) is considered as another 
mammalian source that can be used to obtain gelatine 
without any religious or even cultural barriers around the 
world. The global consumption in 2013 was estimated at 
8.6 million tonnes whereby the per capita consumption 
was around 1.2 kg with the global population of 7.2 
billion people. Its consumption is mainly concentrated in 
countries such as China, Australia, South Africa and New 
Zealand. The total world production of sheep and goat 
meat has increased from 11 billion pounds or about 500 
thousand metric tonnes in 1965 to 18 billion pounds or 
about 8 million metric tonnes in 2011. China is the largest 
producer with 4.4 billion pounds or about 1 million metric 
tons, followed by the European Union (1.9 billion pounds 
or about 860 thousand metric tons), Australia (1.4 billion 
pounds or about 635 thousand metric tons) and New 
Zealand (1 billion pounds or about 453 thousand metric 
tons). Although world production has increased, demand 
has increased more than supply and this has resulted in 
record prices over the past 2 years. The World per capita 
lamb, mutton, and goat consumption has increased from 
3.95 pounds in 1965 to 4.17 in 2007 (Brester 2012).
EqUINE
In China during the Tang Dynasty gelatine was sourced 
from the hide of Equus asinus l. also known as donkey 
because it was believed the efficacy of donkey hide is the 
best due to its quality such as hard, brittle and with shiny 
sections. The fragment is brown and translucent if held up 
to the light, having a slight odour and slightly sweet flavour. 
It is consumed as E Jiao herb, a common Chinese herb 
which has long been used as a blood tonic in traditional 
Chinease medicine practice such as to replenish vital 
energy (qi) and nourish blood (Liu et al. 2014). Official 
statistics from the People’s Republic of China indicates 
that 90% of the country’s ejiao products are made in 
Shandong Province which is about 5,000 tonnes. Even 
though, having constrains in donkey hide production due 
to the animal’s low fertility rate and long rearing period, 
causes an annual price hike with a great demand for its’ 
gelatine (ShanghaiDaily.com 2016).
POUlTRY (CHICKEN)
Over the years, there has been a shift in protein source 
consumption from the known mammalian source, also 
known as ‘red meat’ to be considered as healthier poultry, 
known as ‘white meat’ such as chicken or turkey. The 
total world poultry production has seen it growing and 
even undergoing various difficulties such as ‘bird flu’. The 
estimated production growth in South East Asia is nearly 
3-8% as in Table 2. The tremendous growth in poultry 
production is due to the switching of consumer preference 
resulting in an increase in demand. This increase of chicken 
meat consumption is due to the versatility of the meat and 
also socioeconomic factors such as relatively low cost in 
comparison to other types of meat, increase in household 
income, acceptance of chicken meat to most religions 
and perceptions that poultry meat is healthier than other 
types of meat (Jayaraman et al. 2013; Norimah et al. 2008; 
Zhang et al. 2010). 
The processing of chicken would lead to enormous 
amounts of waste materials such as skin, bones and shank 
which could be used as an essential alternative source for 
gelatine production. Synergistically, it would effectively 
improve the waste management of poultry industry and 
enhance efficient environmental friendliness. This in 
return, will also help to overcome the increasing demand 
for gelatine usage worldwide and in-depth research of its 
physicochemical research which is being carried out due to 
the pricing and commitments of industrial farmers (Abdullah 
et al. 2016; Lasekan et al. 2013; Rafieian et al. 2013). 
MARINE/FISH
The marine source is also one of the recently being 
researched as a possible contributor to gelatine alternative 
to mammalian gelatine, especially fish sourced. One of the 
major advantages of fish gelatine is that it can be accepted 
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by people from all religions and not associated with BSE 
outbreak. Some fish gelatines are available commercially, 
although they are not well-characterized. Fish gelatine 
represents less than 1% of total world gelatine output 
(Irwandi et al. 2009; Wang et al. 2008). Its disadvantages 
or inability to penetrate the market is due to its sustainable 
large volume availability of raw material or commitment of 
fish gelatine producers, difficulty in obtaining certification 
on raw fish material which is essential for traceability 
in food additives especially from animal sources, price 
constrain compared to present source gelatine, inferior 
rheological or gelling properties, presence of odour and 
off-flavour of fish gelatine (Karim & Bhat 2009; Schrieber 
& Gareis 2007).
As compared to the more established mammalian 
gelatine, literature on the properties of fish gelatine as a 
pharmaceutical excipient is very limited. Fish gelatine has 
been studied mainly for its application in food industries 
and the quest for fish-sourced gelatine is a promising 
prospect. Aquaculture business in the country has involved 
many fish farmers and commercial companies practising 
several types of production systems. However, they almost 
exclusively use unimproved species and strains. It appears 
that presently available knowledge and experience in 
aquaculture systems management are not fully exploited to 
achieve a sustained yield and optimum fish performance. 
In this context, the growth and utilisation of genetically 
improved stocks that are more productive becomes 
imperative in order to effectively use the resources. 
The increase in world tilapia production accompanied 
by a significant increase in tilapia industry has led to the 
production of a lot of waste in the forms of collagen-
rich skins and bones which could be a valuable raw 
material for gelatine production (Songchotikunpan et al. 
2008). However, hatchery operators and fish farmers in 
Malaysia, for example, have used the available tilapia 
strains without discriminating the history, background, 
performance and pedigree information. Improper brood 
stock management associated with high level of in-
breeding has also ensued in a decline in productivity 
of cultured populations under various commercial 
backgrounds. Periodically, the tilapia broodstock has 
also been imported into Malaysia by private hatcheries. 
Crossbreeding and hybridisation are mostly practised to 
improve the strains performance. Traits such as growth, 
survival rate, body conformation and colour are of 
primary concerns in producing new hybrids.
At the moment, these wastes are either discarded, 
causing environmental pollution, or turned into low-value 
products like fertilisers and animal feeds. Utilisation of 
tilapia skin gelatine as a pharmaceutical excipient will 
not only provide an alternative source of gelatine which 
is accepted by most religions and support groups but also 
eliminates the scar of bovine spongiform encephalopathy 
related to mammalian gelatine (Karim & Bhat 2009).
OTHER RAW MATERIAlS (EDIBlE INSECTS)
FAO predicts due to nations challenging for industrial 
development against each other, there will be a reduction 
in agricultural land, fishery, and nutrients. As most parts of 
Africa, certain parts of Asia practise entomophagy whereby 
some communities have reported to consume different 
kinds of insects as their daily meals. Thus, some experts 
TABlE 2. i Indigenous chicken meat production in Asia. Global Poultry Trends-Asia Accounts for a Third of Chicken Meat Output 
by http://www.thepoultrysite.com/articles/3533/.
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have estimated the potential growth due to alternative 
protein source to animal livestock and its benefits, such 
as efficiency, lower resources, increase in food security, 
environmental and economic sustainability (Gahukar 2011; 
Halloran et al. 2016; Premalatha et al. 2011; Rumpold & 
Schlüter 2013). Recent studies have been carried out to find 
an alternative gelatine source which was explored as halal 
gelatine consisting two types of Sudanese edible insects 
such as Aspongubus viduatus (melon bug) and Agonoscelis 
pubescens (sorghum bug). It was even demonstrated to be 
used as an ingredient in ice creams. It is considered halal 
but its acceptance due to religious viewpoint only and 
mainly in the African continent due to economic growth, 
steady decline in poverty rates which continues to grapple 
the food security and undernourishment of their population 
(Mariod & Fadul 2015; Mariod et al. 2011).
APPlICATIONS OF GElATINE IN VARIOUS INDUSTRIES
Pharmaceuticals Gelatine fulfils a versatility in 
pharmaceutical industry application due to its unique 
chemical characteristics and considered as a ‘GRAS’ 
drug delivery excipient material in vast pharmaceutical 
dosage forms, such as pastilles, troches, microcapsules, 
suppositories, effervescent tablets, sub-coating agents, 
and constituent in wound care products (Sahoo et al. 
2015). In cases, due to severe injuries with heavy blood 
loss, volume replacement fluid is most sought after such 
as crystalloids or colloids. Colloidal plasma expanders, 
especially gelatine as the active ingredient is the most 
sought after as compared to others in its class due to side 
effects of the polysaccharide i.e. HES (hexaethyl starch) 
plasma expanders or even crystalloids. The main reasons 
are due to its viscosity and molecular properties which 
are similar to normal blood, that the HES plasma expander 
due to its complications such as higher molecular weight 
especially of its third generations which is about 130 kDa. 
There are newer generation being developed with a lower 
molecular weight, thus might result in lesser instances of 
kidney failure. As for now, it is used with or in caution, in 
medical case to case basis (lira & Pinsky 2014; Saw et al. 
2012; Zarychanski et al. 2013). The reason these volume 
expanders are administered into the bloodstream via an 
infusion, is in order to increase the amount of fluid in the 
bloodstream, thus preventing the onset of hypovolemic 
shock and stabilising the circulatory system. The body 
quickly and completely reabsorbs the gelatine within the 
blood substitutes. 
While gelatine is  omnipresent,  in various 
pharmaceutical applications, such as oral applications, 
hard or soft elastic capsules shells, formulation of tablets 
due to its natural binding, disintegration agent that 
meets the requirements of concerned consumers about 
the use of synthetic or chemically modified ingredients. 
Gelatine is further employed as a viscosity enhancer in 
liquid and semisolid preparations such as emulsions, a 
coating agent to encapsulate dry powders which are then 
released when administered orally, also plays a role in the 
formulation of prolonged release matrices, can be treated 
with formaldehyde to produce a gastro-resistant coating 
(natural protective) and reduce unpleasant taste along with 
the aroma.
Till todate, there are further research being carried 
out to improvise the gelatine cross-linking especially for 
the capsule dosage, in order to improve their shelf life at 
high temperature and humidity. This new technology, even 
allows the pharmaceutical industry to explore new capsule 
fillings and expand their distribution into regions that are 
exceptionally hot and humid. 
The chalky, unpleasant, inconvenient and bad 
tasting traditional medicinal products are delivered by an 
alternative delivery method or dosage form as gelatine 
gummies for children’s vitamins and minerals. Thus, at 
present due to its market growth now, its expanding further 
into the adult dosage form category.
Cosmetics and cosmeceuticals  Cosmetics and 
cosmeceutical segment was identified as the largest 
application of global collagen peptide market, with a total 
volume of over 4,000 tonnes, in 2013 (Research 2014). 
Recently gelatine used in many cosmetics and healthcare 
products such as collagen in tropical cosmetics creams due to 
its anti-aging properties or wrinkle reducer or stretch marks, 
along with replenishing and rejuvenating the skin, which 
accentuated its use in cosmeceuticals products. Hence, 
accretion growth in its market share of cosmeceuticals as 
an ingredient in face creams, body lotions, shampoos, hair 
sprays, sunscreens bath salts and bubbles.
This is due to dermatologically tolerated, effective 
moisturiser and film-forming properties help in collagen 
depletion, which usually starts around the early age in 
humans and continues to accelerate further as cellulite. 
Moreover, for many years, it has been used in the cosmetics 
industry as ‘hydrolysed animal protein’ as hair conditioning 
agent in shampoos, conditioners, lipsticks and fingernail 
formulas and it helps to maintain hair thickness or strength. 
Whereas for other cosmetics products such as face mask, 
it can smoothen and strengthen skin texture. But due to 
recent developments and most peoples’ misunderstanding/ 
misconception, its use has decreased considerably as 
more brands move away from formulating cosmetics with 
animal-derived ingredients.
Food Gelatine has numerous benefits in the food 
production as it is the main source for excellent protein 
supplement as contains amino acids for body cells and 
tissue nourishment for improvement such as hair quality, 
growth, texture and skin health by providing more or less 
elasticity, low in calories, free of cholesterol, sugar and fat. 
Consuming gelatine or collagen directly can help improve 
appearance due to its effects on skin health and cellular 
rejuvenation by stimulating new and non-fragmented 
collagen thus making it useful as an anti-ageing substance. 
It is easily digested thus, is used as an excellent gelling 
agent, binding, or glazing agent for the preservation 
of fruits and meats (Varela & Fiszman 2013). It is also 
used as film coatings to improve appearance or texture 
of food, reduces water loss, heal digestive disorders, 
clarification of beverages and juices. It is further used in 
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the production of jellied desserts and confectionery such 
as ice creams, yoghurts, chewy toffees, marshmallows, 
sauces and countless other food products (Baldwin et al. 
2011; Schrieber & Gareis 2007). As the food industry 
develops the dietary supplements are now given more 
focus by athletes in order to maintain their weight and 
providing energy before workouts. Therefore, nutritional 
bars containing gelatine are given much more emphasis.
Daily consumption of certain amounts of gelatine 
has shown improvement of nail strength and growth 
rate. Whereas for joint and bone health, it reduces 
joint pain related to arthritis. According to the Gelatin 
Manufacturers Institute of America, there are other 
food items that contain gelatine. They are fruit chews, 
gummy snacks, gum drops, marshmallows, puddings, 
ice-cream, yoghurt, cream pie and wafers. Commercially 
baked cupcakes and frosted fruit tarts frequently contain 
gelatine, as well. This is due to its ability in providing 
varying degrees of texture and elasticity it is able to 
replace partially the high-fat content in many products. 
The development of many of the low-fat products, such 
as half-fat margarine, fat-reduced cheese and yoghurt 
varieties, can be found in most food products.
Its consumption is also suggested as a sleep aid 
due to the presence of glycine, which helps to improve 
sleep cycles by stimulating certain neurotransmitters and 
enzymes which in turn increases the quality and duration 
of sleep. Proper sleep cycles and rest for the body is 
important for the general function and metabolism of 
the body, in order to help muscle building in many ways 
for the athletes. 
lately, there is further research being carried out to 
use gelatine as development as food packaging materials 
incorporated with natural antioxidants and antimicrobials 
thus having the same principal as film forming application 
in food products to extend food shelf-life and reducing 
food loss (Etxabide et al. 2017; Nur Hanani et al. 2014). 
Tissue Regeneration or Engineering Tissue regeneration 
or engineering is considered as restoration and is a 
significant alternative solution for the treatment of 
traumatised, damaged or lost tissue, bone and cartilage 
or organ failure. It has brought a new paradigm shift and 
cutting edge for the healing of musculoskeletal conditions. 
It is carried out by implanting a natural, synthetic, or 
semisynthetic tissue, bone or organ which mimics as 
a fully functional, from the start or that grows into the 
required functionality. Development of tissue regeneration 
or engineering is divided into three basic elements that are 
cells, biodegradable scaffolds and growth factors. Gelatine 
plays a crucial developmental role as a biomaterial for 
the use as an artificial valve, bone and tissue regeneration 
due to its less immunogenic compared with its precursors. 
Its chemical modification has enormous potential, with 
suitable characteristics in the development of new 
nanomedicines and biomedicines. The modification of the 
gelatine protein biopolymer is based on the transformation 
of the carboxylic group into amido groups after their 
reaction with polyamines. Basically, it is due to the 
presence of informational signals like the Arg–Gly–Asp 
[RGD] sequence, helps promote cell adhesion, migration, 
differentiation and proliferation (Hoque et al. 2015; lopez-
Cebral et al. 2011; Persidis 1999; Silva et al. 2010; Zhu 
& Marchant 2011) This gelatinous mixture resembling 
similarly to tissues in the extracellular environment, plays 
a vital role as scaffolds for cell differentiation, tissue 
vascularization, angiogenesis and regenerate cartilage.
Further research is being carried out using crosslink 
with gelatine in ocular applications such as repair of 
the ocular components, used as a composite sponge 
providing sufficient structural support to the defect bone 
sites while enhancing the body’s own reparative capacity 
and orthopaedic application such as osteochondral repair 
in a rabbit osteochondral defect model, whereby gelatine 
or collagen is the popular biomaterial choice. It has also 
been used in other areas such as bladder, skin and airways. 
The combination used in bone tissue engineering scaffolds 
with drug delivery capability, is increasingly researched 
as gelatine plays a vital role as a drug carrier to tissue 
sites, thus ultimately eliminating the need for autologous 
tissue harvesting or repeat operations (Mazaki et al. 2014; 
Mouriño et al. 2013; Murphy et al. 2013). 
concluSion
This review provides an overview on the importance 
of alternative sources for gelatine in food, cosmetics 
and pharmaceuticals. As the consumption or demand is 
increasing the raw materials required to produce gelatine 
become exhaustive, alternative source of gelatine having 
similar characteristics and properties as to presently 
available gelatine products is very much needed and has to 
be further researched. Furthermore, gelatine from Gallus 
gallus domesticus can be a good alternative source of 
animal protein to be used either as an excipient or as an 
active ingredient of a drug formula. It can also help the 
industry economically where wastage is reduced, and usage 
enhanced using newly developed and improved technology. 
Sustainable growth at present world consumption rate can 
also be guaranteed.
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